About Iodine-125 and Palladium-103 Plaques

A gold eye-plaque (front and back) and silicone insert
A gold eye-plaque (front and back) and silicone insert – seed carrier.

Ophthalmic plaque radiation therapy is the most commonly used “eye and vision-sparing” treatment for choroidal melanoma (around the world). A radioactive plaque is a small, dish-shaped device that contains a radioactive source.

In order to visualize the intraocular tumor during surgery, a bright light is placed on the eye. This is called transillumination. The thick and pigmented tumor within the eye blocks the light, creating a shadow or dark spot on the wall of the eye.

Visualizing the intraocular tumor
In order to visualize the intraocular tumor, during surgery, a bright light is placed on the eye. The thick tumor within the eye commonly blocks the light creating a shadow or dark spot on the wall of the eye.

The edges of the shadow is marked (on the sclera) with a temporary tissue marker.Low-energy radioactive eye-plaques contain rice-sized iodine-125 or palladium-103 seeds that emit low energy photon (23-28 KeV) radiation. This radiation is effectively blocked by the gold-backing of the plaque creating a directional source.

Typically, the radioactive eye-plaque is then sewn onto the eye as to cover the intraocular tumor shadow, plus a 2-3 mm “free-margin.” This extra margin is used to make sure that the tumor is always under the plaque during radiation. With the plaque in place, radiation is continuously delivered over 5 to 7 days, and then removed.

The first plaques incorporated the radioactive material Cobalt-60 and later included Ruthenium-106 and Iodine-125. In 1990, palladium-103 (Pd-103) became available for the first time for treatment of intraocular tumors.

the radioactive eye-plaque is then sewn onto the eye
Typically, the radioactive eye-plaque is then sewn onto the eye as to cover the intraocular tumor shadow, plus a 2-3 mm “free-margin.”

Multiple dose comparisons (versus iodine-125) showed that palladium-103 (Theragenics Corp. Buford, Georgia) offered a more favorable intraocular dose distribution in most cases. It delivered slightly more irradiation to the tumor while allowing less to be absorbed by the patients surrounding normal structures. Less radiation also reaches the operating surgeon and health-care personnel. Dr. Finger recommends the use of palladium-103 for ALMOST ALL of his patients with choroidal melanoma.

Long-term results on plaque-treated patients are now available.

Reported Results after Ophthalmic Plaque Radiation Therapy

Long-term results on plaque-treated patients

Related Links

Patient Stories

"Very well treated by Dr. Finger. He explained everything I needed to know about my issue with detail and attention, putting me at ease and giving me confidence to handle this problem for the rest of my life.”
N.N.

Read More

REQUEST AN APPOINTMENT

Go to Appointment Form

CONNECT AND SHARE